CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 141 enrolled
Drug / intervention
Hydromorphone HCl OROSdrug
Likely dose
Hydromorphone HCl OROS 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01006356
NCT01006356Phase 4Completed
CompareCT.gov

Cancer Pain Management With Hydromorphone HCl ORal Osmotic System in Korean Cancer Patient: Evaluation of Its Clinical Usefulness in Reduction of Breakthrough Pain Medication Frequency

Janssen Korea, Ltd., Korea·interventional·Posted Nov 2, 2009·Updated Aug 8, 2013

In Brief

A Phase 4 clinical trial evaluating Hydromorphone HCl OROS for Cancer and Pain. Completed, enrolled 141 participants.

Detailed Summary

The purpose of this study is to evaluate the clinical efficacy of hydromorphone hydrochloride (HCl) Oral Osmotic System (OROS) by assessing the extent of reduction of medication frequency for the management of breakthrough pain after the administration of hydromorphone HCl OROS in Korean cancer participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Pain
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2, 2009
Enrollment StartOct 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.7 years ago

Interventions

Hydromorphone HCl OROSdrug

Hydromorphone HCl OROS 8 mg once daily for 2 weeks.